Main topic: Venture firm Andreessen Horowitz co-leads a $200 million investment in Genesis Therapeutics, a biotechnology startup using artificial intelligence for drug discovery.
Key points:
1. Andreessen Horowitz invests $200 million in Genesis Therapeutics.
2. Genesis Therapeutics applies AI to discover medicines against challenging molecular targets.
3. The funding will help Genesis Therapeutics launch its first clinical trials.
Main topic: Genesis Therapeutics' $200 million Series B funding round for its AI-powered drug discovery platform in the biotech sector.
Key points:
1. Genesis Therapeutics closed a $200 million Series B funding round, led by Andreessen Horowitz Bio + Health and an unnamed U.S.-based life-sciences-focused investor.
2. New investors in the round included Fidelity Management & Research Co., BlackRock, and Nvidia’s venture arm NVentures.
3. Genesis Therapeutics plans to use the funding to evolve into a clinical stage company, invest in its AI platform, and expand its discovery pipeline.
Ginkgo Bioworks and Google Cloud have entered into a five-year strategic partnership to develop and deploy AI tools for biology and biosecurity, with Ginkgo making Google its primary cloud services provider and receiving funding for the development of foundation models and applications.
Ginkgo Bioworks has announced a strategic partnership with Alphabet to utilize artificial intelligence (AI) in its biological engineering services, aiming to improve efficiency, but the collaboration alone does not make the stock a buy, as Ginkgo still faces challenges in proving its viability and achieving profitability.
